Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome

Heart and Vessels

Volumn 24, Issue 2, 2009, Pages 73-78

  Brackbill, Marcia L ^a,b   Kidd, Robert S ^a   Abdoo, April D ^a   Warner, James G ^b   Harralson, Arthur F ^a  

^a SHENANDOAH UNIVERSITY   (United States)

^b Winchester Medical Center   (United States)

Author keywords

Clopidogrel; CYP3A; Pharmacogenomics; Polymorphism

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUINDOSTATIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVATION; DRUG STRUCTURE; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; TICLOPIDINE; TREATMENT FAILURE;

EID: 64249124092     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-008-1085-2     Document Type: Article

References (22)

1. Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU, Akgoz H, Ergelen M, Ciloglu F. (2006) Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels 21:102-107
2. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO (2001) ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary. J Am Coll Cardiol 37:2215-2239
3. Murasaki S, Murasaki K, Tanoue K, Kawana M, Hagiwara N, Kasanuki H (2007) Circulating platelet and neutrophil activation correlates with the clinical course of unstable angina. Heart Vessels 6:376-382
4. Steinhubl SR, Berger PB, Mann III JT, Fry ETA, DeLago A, Wilmer C, Topol EJ (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 288:2411-2420
5. Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 45:1157-1164
6. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251
7. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-2913
8. Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647-654
9. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:234S-264S
10. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 10:373-388
11. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, Guyer KE, Tait AR, Bates ER (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166-171
12. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174:1715-1722
13. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247
14. Fisher AA, Le Couteur DG (2001) Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel. Ann Pharmacother 35:1567-1569
15. Kidd R, Johnson M, Richard C, Adkins J, Harralson AF (2006) Frequency analysis and correlation of newer variant alleles of CYP2C9 and warfarin dose (abstract). J Clin Pharmacol 46:1085
16. Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192-199
17. Hsieh FY, Bloch DA, Larsen MD (1998) A simple method for sample size calculation for linear and logistic regression. Statistics Med 17:1623-1633
18. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171-3175
19. Snoep JD, Hovens MCM, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV (2007) Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 154:221-231
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26:1895-1900
21. Smith SMG, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME, Storey RF (2006) Common sequence variations in the P2Y12 and CYP3A5 genes do no explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 17:250-258
22. Kim KA, Park PW, Park J-Y (2008) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236-242